KRAS and colorectal cancer: Excitingly, use of the PDE6d‐KRAS disruptor compounds as warheads for the development of PROTACS enabled rapid and specific PDE6d degradation greatly improved the potency of the compounds, enhanced their ability to inhibit ERK map kinase signaling, and augmented their anti‐proliferative activity against colorectal cancer in vitro and in vivo [34].